- Gross revenues increase by 8.2 percent to 1.6 million Euros

- EBITDA improves to -0.1 million Euros

- Earnings per share increase from -0.04 Euros to -0.02 Euros

- Liquidity of 1.1 million Euros on target

curasan AG (ISIN DE0005494538), a leading specialist for medical devices in the field of bone and tissue regeneration, took off well into the business year 2015. With the published results on the first quarter, again the company is one step closer to reaching profitability in the upcoming year.

During the reporting period gross revenues of curasan AG increased by 8.2 percent to 1.6 million Euros versus 1.5 million Euros in the previous year. The European as well as the North-American Business contributed to this increase. Earnings before interest, taxes, depreciation, and amortization (EBITDA) improved to -0.1 million Euros after -0.2 million Euros in the previous year. Earnings per share subsequently rose to -0.02 Euros after -0.04 Euros in the previous year.

Liquidity was as well on target at 1.1 million Euros, after investments were taken in March into the upcoming product relaunch of our synthetic bone replacement material Osbone in the second quarter. Against this background marketing activities were accelerated and the stock of product units increased.

'At first glance our development was better than expected', Michael Schlenk, the new CEO of curasan since end of 2014, comments on the figures. 'One fact fostering this high growth though, was a shift of revenues into the first quarter we did not expect in our budget planning process before Q2. Considering this, we expect this effect to be compensated in the second quarter and our development to be well in line with our forecast for the year 2015 published just two weeks ago.'

On the basis of a conservative results forecast for the fiscal year 2015 the company expects gross revenues of 6.3 to 6.9 million Euros and a net loss of 1.2 to 1.6 million Euros. The company will progressively specify this forecast with every release of upcoming quarterly results.

The complete interim report for the first quarter 2015 in German language is available for download on the company's website at
www.curasan.de/de/investor_relations/zwischenmitteilungen_halbjahresberichte.php

Upcoming capital markets events of curasan AG:

25/06/2015 Annual General Meeting 2015 Aschaffenburg

About curasan AG:
curasan AG specializes in medical products for bone and tissue regeneration in the segment of regenerative medicine. It has set up a ground-breaking product pipeline of synthetic substitution and regeneration materials. Numerous patents and a comprehensive list of scientific documentation have established the clinical success of the products and the highly innovative strength of curasan AG. The list of users include surgically active dentists, implantologists and oral, maxillary and dentofacial surgeons, as well as orthopaedics, traumatologists and spinal column surgeons. The company is listed in the General Standard at the Frankfurt Stock Exchange (ISIN: DE 000 549 453 8).